SCHEMBL828618

SCHEMBL828618

NC(=O)c1nc2ccccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.59
JAK2 O60674 1/20 0.59
ABL1 P00519 1/20 0.59
NTRK1 P04629 1/20 0.59
LCK P06239 1/20 0.59
FYN P06241 1/20 0.59
CSF1R P07333 1/20 0.59
RET P07949 1/20 0.59
IGF1R P08069 1/20 0.59
MET P08581 1/20 0.59
PDGFRB P09619 1/20 0.59
PIM1 P11309 1/20 0.59
FGFR1 P11362 1/20 0.59
PRKACA P17612 1/20 0.59
KDR P35968 1/20 0.59
MAP2K2 P36507 1/20 0.59
CDK8 P49336 1/20 0.59
GSK3A P49840 1/20 0.59
GSK3B P49841 1/20 0.59
CDK7 P50613 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688264 1.00 AURKA (0.59) AURKAJAK2ABL1NTRK1LCK
Hydrochloric Acid SCHEMBL5008172 0.98 AURKA (0.58) AURKAJAK2ABL1NTRK1LCK
Hydrochloric Acid SCHEMBL2674335 0.98 AURKA (0.58) AURKAJAK2ABL1NTRK1LCK
Trifluoroacetic Acid SCHEMBL5659985 0.89 FAAH (0.49) AURKAJAK2ABL1NTRK1LCK
Indole SCHEMBL2364137 0.87 FAAH (0.54) AURKAJAK2ABL1NTRK1LCK
SCHEMBL28793290 0.86 FAAH (0.47) AURKAJAK2ABL1NTRK1LCK
SCHEMBL250171 0.84 CCND3 (0.70) AURKAJAK2ABL1NTRK1LCK
SCHEMBL5358948 0.82 AURKA (0.61) AURKAJAK2ABL1NTRK1LCK
SCHEMBL160155 0.82 AURKA (0.61) AURKAJAK2ABL1NTRK1LCK
Hydrochloric Acid SCHEMBL7000982 0.82 CCND3 (0.68) AURKAJAK2ABL1NTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 833 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
US-20250082652-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2025-03-13 US claimed
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS QLi5 Therapeutics AG (DE) 2024-12-19 US claimed
CN-118996552-A Electroplating solution for insoluble anode and electroplating copper process thereof 广东硕成科技股份有限公司 2024-11-22 CN claimed
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP claimed
EP-3720493-B1 COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES UNIV KOELN (DE) 2024-07-24 EP claimed
WO-2024109642-A1 USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR 常州大学 2024-05-30 WO claimed
CN-117794896-A Protease inhibitors for the treatment of coronavirus infections 斯克里普斯研究学院 2024-03-29 CN claimed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 EP claimed
WO-2023131576-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2023-07-13 WO claimed
WO-2003055877-A1 USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 ASTRAZENECA AB (SE) 2003-07-10 WO claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed
EP-1299382-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-09 EP claimed
WO-2002064586-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-08-22 WO claimed
WO-2002004440-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-17 WO claimed
WO-2000027394-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2000-05-18 WO claimed
CN-1081563-A High efficient poisonless spray mildew preventive QIU GEPING (CN) 1994-02-09 CN claimed
CN-86105414-A WOOD TREATMENT COMPOSITION 1988-03-23 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA AURKA 1229/4885JAK2 911/4885ABL1 796/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 AURKA 1989/4885JAK2 77/4885ABL1 200/4885
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS PSMB5, PSMA5, PSMB1 AURKA 3139/4885JAK2 3470/4885ABL1 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.